Skip to main content
    B

    Barinthus Biotherapeutics plc (BRNS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • PINK

    $0.74
    +0.00 (+0.00%)

    Market Cap: $30.23M

    Last updated: Oct 14, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(16/22)
    Avg Surprise
    +32.79%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.26
    Range$-0.27 - $-0.25
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.29+10.3%
    60d ago$-0.29+10.3%
    30d ago$-0.29+10.3%
    7d ago$-0.25-4.0%
    Current$-0.26
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.11 - $-0.08
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.26---
    Jun 26
    Reported Aug 6
    		$-0.26$-0.28+7.14%Beat+50.0%
    Mar 26
    Reported Apr 30
    		$-0.14$-0.28+50.00%Beat+71.4%
    Dec 25
    Reported Mar 13
    		$-0.27$-0.39+29.82%Beat-33.7%
    Sep 25
    Reported Nov 7
    		$-0.24$-0.39+38.46%Beat-14.3%
    Jun 25
    Reported Aug 7
    		$-0.52$-0.29-79.31%Miss-20.9%
    Mar 25
    Reported May 7
    		$-0.49$-0.36-36.11%Miss-22.5%
    Dec 24
    Reported Mar 20
    		$-0.20$-0.37+45.38%Beat+55.1%
    Sep 24
    Reported Nov 6
    		$-0.21N/A+52.27%Beat+43.2%
    Jun 24
    Reported Aug 8
    		$-0.43$-0.41-4.88%Miss+30.6%
    Mar 24
    Reported May 13
    		$-0.40$-0.61+34.43%Beat+16.7%
    Dec 23
    Reported Mar 20
    		$-0.45$-0.50+10.00%Beat+21.1%
    Sep 23
    Reported Nov 9
    		$-0.37$-0.55+32.73%Beat-268.2%
    Jun 23
    Reported Aug 10
    		$-0.62$-0.59-5.08%Miss-244.2%
    Mar 23
    Reported May 12
    		$-0.48$-0.58+17.24%Beat-785.7%
    Dec 22
    Reported Mar 30
    		$-0.57$-0.42-35.71%Miss-50.0%
    Sep 22
    Reported Nov 10
    		$0.22N/A+142.31%Beat+269.2%
    Jun 22
    Reported Aug 9
    		$0.43$-0.40+207.50%Beat+167.2%
    Mar 22
    Reported Jun 29
    		$0.07N/A+122.58%Beat+103.7%
    Dec 21
    Reported Mar 30
    		$-0.38$-0.58+34.48%Beat+99.6%
    Sep 21
    Reported Nov 12
    		$-0.13N/A+56.67%Beat-103.9%
    Jun 21
    Reported Aug 12
    		$-0.64$-0.59-8.47%Miss+99.2%
    Mar 21
    Reported Jun 29
    		$-1.90$-2.11+9.95%Beat+97.6%
    Dec 20
    Reported Dec 31
    		$-92.90N/AN/ABeat-
    Sep 20
    Reported Sep 30
    		$3.32N/AN/ABeat-
    Jun 20
    Reported Jun 30
    		$-75.31N/AN/ABeat-
    Mar 20
    Reported Mar 31
    		$-80.20N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.81EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-52.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-796.09x
    Current Ratio5.54xQuick Ratio5.54x
    Trading Statistics
    Beta-0.36Avg VolumeN/A
    52-Week High$1.5052-Week Low$0.51

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.74
    SMA 20$0.74
    SMA 50$0.70
    SMA 200$0.66
    EMA 10$0.74
    EMA 20$0.74
    EMA 50$0.71
    EMA 200$0.71

    MACD

    Line: 0.01Signal: 0.01Hist: -0.00

    ADX

    ADX: 28.2+DI: 25.1-DI: 14.0

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down36.0
    PSAR$0.75

    Bollinger Bands

    Upper Band$0.74
    Lower Band$0.74
    %B Position2%(Lower)
    Band Width0.62

    RSI (14-Day)

    Neutral
    60.3

    Momentum Oscillators

    Stoch %KN/A
    Stoch %D33.3
    Williams %RN/A
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)41.7
    MFI (14d)N/A

    Volatility Measures

    ATR (14d)$0.01(1.2%)
    StdDev (20d)N/A
    Hist Vol0.1%(Low)

    Volume Flow

    VWAP$0.74
    OBV75.6M
    AD Line-40.5M
    CMF (20d)N/A

    Volume Metrics

    Avg Vol (20d)N/A
    Vol RatioN/A
    VWMA (20d)N/A

    Pivot Points

    R3$0.74
    R2$0.74
    R1$0.74
    Pivot Point$0.74
    S1$0.74
    S2$0.74
    S3$0.74

    Advanced Oscillators

    TSI21.08
    Ultimate OscN/A
    KST60.17

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$-9,173,000$14.97M$0$0$5.37M$0
    Cost of RevenueN/A$854,565$907,686N/A$2.02M$2.04M$69,000$1.49M$1.47M$1.43M$1.45M$1.47M
    Gross ProfitN/A$-854,565$-907,686N/A$-2,024,681$-2,041,809$-69,000$14.97M$-1,469,000$-1,429,000$3.92M$-1,465,000
    Operating Expenses$11.02M$8.25M$8.50M$15.07M$23.32M$20.60M$23.32M$24.35M$18.29M$16.91M$19.99M$16.11M
    R&D$3.92M$3.59M$3.93M$5.15M$6.61M$7.99M$9.11M$10.53M$10.97M$10.53M$5.83M$13.94M
    SG&A$7.10M$2.53M$4.58M$5.17M$15.38M$12.64M$3.37M$13.42M$7.20M$5.99M$13.62M$961,000
    Operating Income$-11,019,000$-9,105,712$-9,411,383$-15,066,000$-23,324,000$-20,600,000$-23,390,000$-9,380,000$-18,286,000$-16,914,000$-19,988,000$-16,105,000
    Interest Income$343,000$350,000$406,000$472,000$523,000$556,000$637,000$631,000$635,000$775,000$571,000$196,000
    Interest Expense$14,000$12,978$12,981$13,000$12,000$13,000$12,000$17,000$12,000$12,000$7,000$7,000
    Income Before Tax$-10,622,000$-5,689,448$-11,259,708$-14,642,000$-21,151,000$-19,680,000$-20,588,000$-8,132,000$-16,950,000$-15,557,000$-18,110,000$-14,713,000
    Income Tax Expense$-23,000$-164,723$-172,750$-71,000$-25,000$-22,000$3,000$-3,000$-7,000$-37,000$-820,000$-603,000
    Net Income$-10,580,000$-5,521,729$-11,073,977$-14,566,000$-21,124,000$-19,648,000$-20,540,000$-8,114,000$-16,931,000$-15,489,000$-17,293,000$-14,072,000
    EBITDA$-9,788,000$-4,820,470$-10,337,727$-13,728,000$-19,138,000$-17,633,000$-19,148,000$-6,640,000$-15,471,000$-14,115,000$-16,668,000$-13,232,000
    EBIT$-10,608,000$-5,676,470$-11,246,727$-14,629,000$-21,139,000$-19,667,000$-20,576,000$-8,115,000$-16,938,000$-15,545,000$-18,103,000$-14,706,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BRNS

    News

    Price to earnings forward of Barinthus Biotherapeutics plc Sponsored ADR – SWB:2AB

    This article provides financial information for Barinthus Biotherapeutics plc Sponsored ADR (SWB:2AB), specifically its price to earnings forward ratio. The company is listed on the Stuttgart Stock Exchange. The content...

    TradingView•9/21/26•Neutral

    Oxford Science Enterprises Sells Entire 8.8 Million Share Stake in Barinthus Biotherapeutics

    Oxford Science Enterprises plc has fully divested its 8,797,770 shares in Barinthus Biotherapeutics at $0.11 per share, reducing its ownership to zero. This transaction, executed on September 9, 2026...

    Kalkine Media•9/14/26•Bearish

    Clywedog Therapeutics, Inc. completed the acquisition of Barinthus Biotherapeutics plc from a group of shareholders in a reverse merger transaction.

    Clywedog Therapeutics, Inc. has successfully completed its acquisition of Barinthus Biotherapeutics plc through a reverse merger transaction. The deal, which finalized on September 9, 2026...

    www.marketscreener.com•9/9/26•Neutral

    Barinthus Biotherapeutics Announced Transfer or Voluntary Withdrawal of Listing

    Barinthus Biotherapeutics (BRNS) announced its intention to withdraw and delist its ADSs from Nasdaq following a UK scheme effective September 3, 2026. Trading is expected to halt before September 3...

    TradingView•8/25/26•Bearish

    Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

    Barinthus Biotherapeutics plc announced an update on its proposed all-stock combination with Clywedog Therapeutics, Inc. The Scheme Exchange Ratio has been determined at 0.111...

    GlobeNewswire•8/24/26•Somewhat-Bearish

    BRNS Valuation and Fair Value

    P/E
    -0.8x
    P/B
    0.5x
    See GNG's fair value

    BRNS Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -52.4%

    BRNS Competitors

    CompanyTicker
    Actinium Pharmaceuticals IncATNM
    DocGo IncDCGO
    Milestone ScientificMLSS
    NextCure IncNXTC
    CEL-SCI CorpCVM
    Nortech Systems IncorporatedNSYS
    Rockwell Medical IncRMTI
    Picard Medical, Inc.PMI

    Sector: Healthcare

    BRNS Bull Case vs Bear Case

    Bull case

    • BRNS beat EPS estimates in 75.0% of its last 8 reported quarters.

    Bear case

    • BRNS's quarterly revenue changed -100.0% year over year.

    BRNS Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    13.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.26
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About BRNS

    Does BRNS pay dividends?

    Barinthus Biotherapeutics plc (BRNS) does not currently pay a regular dividend.

    What is BRNS's market cap?

    Barinthus Biotherapeutics plc (BRNS) has a market capitalization of $30.23M with a current stock price of $0.74.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In